期刊文献+

人端粒酶逆转录酶基因反义核酸结合位点的筛选 被引量:2

Screening of antisense accessible sites of human telomerase reverse transcriptase gene
原文传递
导出
摘要 目的筛选人端粒酶逆转录酶(hTERT)基因的反义核酸结合位点。方法合成20mer随机寡核苷酸文库,与体外转录的全长hTERTcRNA杂交,RNaseH切割后,经引物延伸、放射自显影,筛选出26个反义结合位点(AAS)。结合RNAstructure软件分析,选定具有显著茎环结构的7个位点作为最佳反义结合位点,合成其反义寡核苷酸(AS-ODN),转染前列腺癌细胞PC-3,运用噻唑蓝(MTT)比色及逆转录-聚合酶链反应(RT-PCR)分别对前列腺癌细胞生长抑制及hTERTmRNA表达情况进行检测。结果AS—ODN1—7转染前列腺癌细胞PC-3后,细胞生长受到明显抑制,其中AS-ODN3的抑制作用最明显(40.6±1.0)%,与各组抑制率差异有统计学意义(P〈0.05),hTERTmRNA表达水平亦受到明显抑制,亦以AS—ODN3的抑制作用最明显(35.8±1.2)%,与各组抑制率差异有统计学意义(P〈0.05)。结论筛选hTERT基因AAS并合成AS-ODN能有效封闭目的基因。 Objective To screen the antisense nucleic acid accessible sites of human telomerase reverse transcriptase (hTERT) gene. Methods The 20 met random oligonucleotide library was synthesized and then hybridized with in vitro transcripted total hTERT cRNA, then digested by RNase H. After primer extension and autoradiography, 25 antisense accessible sites (AAS) were selected. Seven AAS had obvious stem-loop structure after analyzed by the RNAstructure software. The seven AAS were considered as the best AAS and the complementary antisense oligonucleotide (AS-ODN) were synthesized and transferred into prostate cancer cell line PC-3. Tetrazolium bromide (MTF) colorimetry assay and reverse transcription polymerase chain reaction (RT-PCR) were used to detect the growth inhibition and expression level of hTERT mRNA in prostate cancer cells respectively. Results After AS-ODN1-7 was transferred into PC-3 cells, the AS-ODN3 could significantly inhibit the growth of PC-3 cells (40. 6 ± 1.0) % (P 〈0.05) , and suppress the hTERT mRNA expression ( 35.8 ± 1.2) % ( P 〈 0. 05 ) as compared with other groups. Conclusion To screen AAS of hTERT gene and synthesize there AS-ODAs can block the biological functions effectively.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2011年第12期2101-2104,共4页 Chinese Journal of Experimental Surgery
基金 基金项目:国家自然科学基金资助项目(30860284)
关键词 人端粒酶逆转录酶基因 反义寡核苷酸 引物 hTERT gene Antisense oligonucleotide Primer
  • 相关文献

参考文献9

  • 1Pendino F,Tarkanyi I, Dudognon C, et al. Telomeres and telomerase: pharmacological targets for new anticancer strategies? Current Cancer Drug Targets ,2006,6 : 147-180.
  • 2Olga AK, Jessica K, Utz H, et al. Expression of NES-hTERT in cancer cells delays cell cycle progression and increases sensitivity to genotoxic stress. PLoS One, 2010,5 : 10812.
  • 3Slew PH, Dustin HOB, Barry AS,et al. Potent antisense oligonucleoti- des to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonuclcotide libraries. Nucle- ic Acid Research, 1996,24 : 1901-1907.
  • 4Yuko N, Kuniaki N ,Yuichi O, et al. Telomere length, telomerase activ- ity, and expressions of human telomerase mRNA component (hTERC) and human telomerase reverse transcriptase (hTERT) mRNA in pul- monary neuroendocrine tumors. Japan J Clin Oncol,2007,37:16-22.
  • 5葛莲英,刘剑仑,黎丹戎,张贵年.端粒酶活性和端粒长度在大肠癌组织中的表达及其意义[J].中华实验外科杂志,2004,21(12):1488-1489. 被引量:5
  • 6Angelika G, Stefan K, Doris S, et al. Fast and accurate determination of sites along the FUT2 in vitro transcript that are accessible to anti- sense oligonucleotides by application of secondary structure predictions and RNase H in combination with MAI.DI-TOF mass spectrometry. Nucleic Acids Research,2003,31:79.
  • 7Lloyd BH, Giles RV, Spiller DG, et al. Determination of optimal sites of antisense oligonucleotide cleavage within TNFctmRNA. Nucleic Acids Research ,2001,29:3664-3673.
  • 8高兴成,黄伟佳,钟剑锋,刘平,陈志勇,赖永通.脂质体介导的端粒酶反义寡核苷酸在人膀胱癌EJ细胞中的转染率及稳定性[J].中华实验外科杂志,2006,23(7):856-857. 被引量:10
  • 9Fang HF, Shen YF, John-Stephen T. Native mRNA antisense-accessi- ble sites library for the selection of antisense oligonucleotides PNAs and siRNAs. RNA,2010,16 : 1429-1435.

二级参考文献11

  • 1Blackburn EH.Telomeres:no end in sight.Cell,1994,7:621-623.
  • 2Steensel BV,Lange TD.Control of telomere length by the human telomeric protein TRF1.Nature,1997,385:740-743.
  • 3Hastie ND,Dempster M,Dunlop MG,et al.Telomere reduction in human colorectal carcinoma and with aging.Nature,1990,346:866-868.
  • 4Rhyu MS.Telomere,telomerase and immortality.J Natl Cancer Inst,1995,87:844-894.
  • 5Kim NW.Clinical implications of telomerase in cancer.Eur J Cancer,1997,33:781-786.
  • 6Duncan VE, Ajmani PS, Hughes JA. CeUuar delivery is a major obstacle for olgodeoxynucleotide inhibition of telomerase activity. Anticancer Res, 1998, 18:4105-4108.
  • 7Crooke ST. Progress towards oligonueleotide pharmaeodynamie properties. FASEB J, 1993, 7:533-535.
  • 8Elenitoba-johnson KS. Comples regulation of telomerase activity: implications for cancer therapy. Am J Pathol, 2001, 159:405-410.
  • 9Roth DA, Tawa NE, O'brien JM, et al. Nonviral transfer of the gene encoding coagulation factor Ⅷ in patients with severe hemophilia A. N Engl J Med, 2001,334:1735-1742.
  • 10高兴成,章咏裳,周四维,叶章群,庄乾元.反义寡聚核苷酸抑制人膀胱癌T24细胞系端粒酶活性的研究[J].中华实验外科杂志,2001,18(3):240-241. 被引量:3

共引文献13

同被引文献36

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部